heart failure

TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure Medtech innovation briefing Published: 31 May 2022 www.nice.org.uk/guidance/mib298 pathwaysSummary Summary • The technologytechnology described in this briefing is TriageHF Plus. It is a care pathway that includes a heart failure risk score (HFRS), an online data management platform and telephone assessment. It is used to remotely monitor people at risk of heart failure or worsening heart failure. It must be used alongside Medtronic cardiac implantable electronic devices (CIEDs) and the NICE medtech innovation briefing

Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices Diagnostics guidance Published: 24 October 2024 www.nice.org.uk/guidance/dg61 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility This guidance represents the view the introduction of new devices and procedures. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Heart failure algorithms for remote monitoring in people with cardiac implantableelectronic devices (DG61)© NICE 2024. All rights reserved

Treatment options for Heart Failure with Preserved Ejection Fraction GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid lowering to prevent cardiovascular diseaseMenopauseMenopauseOsteoporosisOsteoporosisStroke and TIAStroke and TIAT2DMType 2 Diabetes MellitusTreatment options forHeart Failure with Preserved Ejection FractionHeart failure is a common complex clinical syndrome of symptoms and signs caused by impairment of the heart’s action as a pump supporting the circulation.Heart Failure with Preserved Ejection Fraction

Treatment options for Heart Failure with Reduced Ejection Fraction GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid lowering to prevent cardiovascular diseaseMenopauseMenopauseOsteoporosisOsteoporosisStroke and TIAStroke and TIAT2DMType 2 Diabetes MellitusTreatment options forHeart Failure with Reduced Ejection FractionHeart failure is a common complex clinical syndrome of symptoms and signs caused by impairment of the heart’s action as a pump supporting the circulation.Heart Failure with Reduced Ejection Fraction (HR

Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation * Text only * * Home * Journals * * Other NIHR research * * For authors

Integrating Palliative Care and Heart Failure: the PalliatHeartSynthesis realist synthesis Integrating Palliative Care and Heart Failure: the PalliatHeartSynthesis realist synthesis * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National Institute for Health and Care Research Select EME GHR

show accompanying symptoms of the underlying disease(s) or risk factors such as tachycardia, tachypnoea, oedema, ascites, pain, hypertension, cardiac arrhythmias, individualized treatment must be ensured in accordance with the generally accepted state of scientific knowledge. According to the G-BA, the adequate treatment of the existing underlying diseases (in addition to heart failure, e.g . myocarditis, cardiomyopathies) or the accompanying symptoms should be comprehensibly documented in the dossier based on the patient characteristics (e.g. oedema, cardiac arrhythmias, etc.). The aetiology of heart failure (congenital heart defects, inadequate success of surgical correction, dilated or restrictive cardiomyopathy, myocardial involvement in genetic muscle diseases and metabolic defects) must

function and BP is minimal and this agent should be considered in patients with a current or recent WHF despite GDMT.Last, the selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with HFrEF. Its effect on cardiovascular outcomes was studied in the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure in a multidisciplinary setting.6Last, frailty can sometimes be reversed with physiotherapy, occupational therapy, and nutrition; therefore, referral for cardiac rehabilitation should be considered. Altogether they might be key to prevent HF-driven cachexia, clinical deterioration, and ultimately autonomy loss.The Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial randomized 349 geriatric

Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association SCIENCE VOLUNTEERWARNING SIGNSAdvanced SearchDONATESkip main navigationClose Drawer MenuHomeCirculationAhead of PrintEvaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease : A Scientific Statement From the American Heart AssociationFREE ACCESSREVIEW ARTICLE PDF/EPUB SectionsToolsShareEvaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart AssociationShahnawaz Amdani, Jennifer Conway, Kristen George, Hugo R. Martinez, Alfred Asante-Korang, Caren S. Goldberg, Ryan R. Davies

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Technology appraisal guidance Published: 1 November 2023 www.nice.org.uk/guidance/ta929 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Empagliflozin for treating chronic heart failure with preserved or mildly

retention. A universal definition of heart failure, proposed in 2021 by the Heart Failure Society of America, the Heart Failure Association of the European Society of Cardiology, and the Japanese Heart Failure Society, describes heart failure as 'a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide of Cardiology guidelines include the objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction or raised LV filling pressure, or raised natriuretic peptides.[3][4][5]In clinical practice, HFpEF was traditionally reported as diastolic heart failure. This was in comparison to 'systolic' heart failure, which is now known as heart failure

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction Technology appraisal guidance Published: 21 June 2023 www.nice.org.uk/guidance/ta902 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart fibrillation, long-term anticoagulants are recommended according to the CHADS-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart fibrillation, long-term anticoagulants are recommended according to the CHADS-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Advanced and Acute Heart Failure The Korean Society of Heart Failure (KSHF) Guidelines provide evidence-based recommendations based on Korean and international data to guide adequate diagnosis and management of heart failure (HF). Since introduction of 2017 edition of the guidelines, management of advanced HF has

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Advanced and Acute Heart Failure The Korean Society of Heart Failure (KSHF) Guidelines provide evidence-based recommendations based on Korean and international data to guide adequate diagnosis and management of heart failure (HF). Since introduction of 2017 edition of the guidelines, management of advanced HF has

A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT * Text only * * Home * Journals * * Other NIHR research * * For authors care for people with heart failure with reduced ejection fraction improved quality of life at 12 months compared with usual care alone. {{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}} Hasnain M Dalal, Rod S Taylor, Jennifer Wingham, Colin J Greaves, Kate Jolly, Chim C Lang, Russell C Davis, Karen M Smith, Patrick J Doherty, Jackie Miles, Robin van Lingen, Fiona C

Assessing and managing frailty in advanced heart failure: An International Society for Heart and Lung Transplantation consensus statement www.jhltonline.orgVerify you are human by completing the action below.www.jhltonline.org needs to review the security of your connection before proceeding.Ray ID: 8642d8c488126437Performance & security by Cloudflare

Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association Guideline-directed medical therapies and guideline-directed nonpharmacological improve quality of life survival in patients with heart failure (HF), but eligible patients, particularly women individuals from underrepresented racial ethnic groups, are often not treated

Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations serum creatinine, encompasses inadequate maintenance sodium and volume homeostasis, retention uremic solutes, disrupted trajectory failure, specific focus (1) conceptual framework appropriate evaluation within context trajectories including consideration therapies; (2) preoperative, perioperative, postoperative approaches surgical therapies (durable left ventricular assist device/heart transplantation) replacement (3) key concepts palliative care decision-making processes unique individuals concomitant disease.